Congenital Heart Block – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Congenital Heart Block Market Outlook
Thelansis’s “Congenital Heart Block
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Congenital Heart Block treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Congenital
Heart Block Overview
Congenital
heart block or atrioventricular block is a loss in the normal function of the
cardiac electroconductive pathways that connect the sinoatrial node (SA node)
to the ventricles via conduction through the atrioventricular node (AV node).
The congenital heart block associated with neonatal lupus is considered a form
of passively acquired autoimmune disease in which maternal autoantibodies to
the intracellular ribonucleoproteins Ro (SS-A) and La (SS-B) cross the placenta
and injure the previously normal fetal heart. Women with serum titers of
anti-Ro antibody carry a 3% risk of having a child with neonatal lupus
syndrome. Recurrence rates are about 18%. Chronic idiopathic fibrosis and
sclerosis of the conduction system in Lenegre’s disease cause half of the
cases. Another common cause is ischemic heart disease, responsible for 40% of
cases. It is associated with hypertrophic obstructive cardiomyopathy and
infiltrative diseases like sarcoidosis and amyloidosis. First-degree congenital
blocks can originate from various locations within the conduction system. The
level of conduction delay includes the atrium, AV node (most common in
first-degree block), Bundle of His, fascicles, Bundle Branches, and Purkinje
system. Mobitz type I second-degree congenital block originates from conduction
system disease below the level of the atrioventricular node. In third-degree
atrioventricular block, no impulses will reach the ventricle and occur in the
atrioventricular node or the intranodal specialized conduction system.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment